La Nanomedicina

Prof. Dr. Josep Samitier Univ. De Barcelona

Lab Nanobioingeniería (IBEC)Coordinador Plataforma Española de Nanomedicina

Director Adjunto CIBER BBN

Informe FENIN 2006 Biotecnologia

MiniaturizaciónTécnicas clásicas (Macro)

Microdispositivos

Nanotecnología

Convergencia de tecnologías

Nuevas Tecnologías

Richard Feynman

Given Imaging Ltd Comercial

Definition: NanoMedicine, for the purpose of this vision document, is defined as the application of Nanotechnology to Health. It exploits the improved and often novel physical, chemical, and biological properties of materials atthe nanometric scale. NanoMedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases.

ETP on Nanomedicine

Entorn internacional

• NIH Nanomedicine Roadmap Initiative, emprendida por el Instituto Nacional de Salud de EE.UU en mayo de 2004 (http://www.capconcorp.com/roadmap04/)

• ESF Scientific Forward Look on Nanomedicine, presentado por el comité de expertos de la European Science Foundation en febrero de 2005 (http://www.esf.org/newsrelease/83/SPB23Nanomedicine.pdf)

• EuroNanoForum 2005, Nanotechnology and the Health of the EU Citizen in 2020 (Edimburgo, 6 – 9 septiembre de 2005).

(2006)

PRESENTACIÓN DEL INFORME

PLATAFORMA ESPAÑOLA DE NANOMEDICINA

PLATAFORMA ESPAÑOLA DE

NANOMEDICINA

Jornadas de Plataformas Tecnológicas

Josep Samitier

Parc Científic de Barcelona-Univ. de Barcelona

Institut de Bioenginyeria de Catalunya (IBEC)

108 grupos diferentes

MIEMBROS

GRUPOS DE TRABAJO

Nanodiagnóstico

Medicina Regenerativa

Liberación de Fármacos

Medicina Regenerativa20%

Educación/ Comunicación22%

Nanodiagnóstico17%

Toxicidad/ Regulación24%

Liberación de fármacos17%

Educación / Comunicación

Toxicidad / Regulación

Por Comunidades Autónomas

Catalunya25%

Galicia7%

Madrid28%

País Vasco18%

C. Valenciana6%

Navarra1%

Canarias1% Andalucía

11% Aragon2%

Asturias1%

MIEMBROS

EURONANOBIO WP1 Experts WorkshopNanobio Clusters: identifying best practices

Dr Arantxa Sanz Prof. Josep Samitier

Institute for Bioengineering of Catalonia (IBEC)Barcelona, SPAIN

WP1:OBJECTIVES AND METHOD

GLOBAL OBJECTIVE: Identifying best practices across the most successful clusters

As integration is key to success in nanobio, success = high quality, common research projects and results (with diverse cluster members as partners)

DATA COLLECTION and ANALYSIS: METHODOLOGY (Feb-May 09)• Definition of a nanobio cluster in the study: research vs innovation cluster• Mapping clusters elsewhere: USA, Canada, Asia-Pacific• Mapping clusters in Europe• Identifying best practices via SWOT analysis • Consolidation workshop: discussion and brainstorming

USA: mapping preliminary results

Research

Clinical

Cluster agency

Innovation

Cluster agency non specific

BAY AREA

SOUTH CALIFORNIA

HOUSTON

CHICAGO

BOSTON

CORNELL

N. CAROLINA

…

ASIA PACIFIC – preliminary results

Research

Clinical

Cluster agency

Innovation

Cluster agency non specific

TSUKUBA / TOKYO

KOBE

YONSEI (SEOUL)

SINGAPORE

SIDNEY …

European Union: mapping preliminary results

Most advanced nanobio clusters across EU + associate states:

-Higher integration level of actors, including hospitals

-Remarkable common output in terms of funded projects, research papers and patents / creation of spin off companies

Research

Clinical

Cluster agency

Innovation

Cluster agency non specific

SWOT analysis: Applying criteria for case studies

STRENGTHS First-class medical researchMaterials science tradition and expertise from oil industryUniversity of Texas system Clinical transfer

WEAKNESSES Number of spin off companies/ Innovation levels: not as high as they might be (compared to California, Massachussets, Chicago)

OPPORTUNITIES Alliance for Nanohealth NIH programme. Purdue Centre of Excellence

THREATSVery specialized on cancer but it cannot be the only one – see the distributed NIH network Health system ???

HOUSTON

SWOT analysis for the mapped clusters (some examples…)

STRENGTHSBioAnalytik Munster: Facilitator, coordinatorIntegration of excellent academic and clinical research Good levels of partnership with industry: Tradition in instrumentationInnovation/ Tech transfer: nanobio start ups

WEAKNESSES Talent attraction : not a capital city

OPPORTUNITIES Very strong support from local government (Munster City council): BrandingSocial capital: easy to network and meet

THREATENSNational support: Other competitive German clusters

MÜNSTER – EXAMPLE